Form 4: DURECT CFO Timothy Papp Granted 46,659 Restricted Stock Units

DURECT Corporation's Chief Financial Officer, Timothy M. Papp, was granted 46,659 shares of common stock in the form of restricted stock units, vesting on July 11, 2026.

Summary

• Timothy M. Papp, Chief Financial Officer of DURECT Corporation (DRRX), acquired 46,659 shares of common stock.
• The acquisition occurred on July 11, 2025, and represents a grant of Restricted Stock Units (RSUs).
• The RSUs were granted at a price of $0 per share.
• Following this transaction, Timothy M. Papp beneficially owns a total of 321,659 shares of DURECT Common Stock.
• The 46,659 RSUs are scheduled to vest 100% on the one-year anniversary of the grant date, contingent upon Mr. Papp's continued service with the company or any affiliate on the vesting date.

Sentiment

Score: 7

Explanation: The grant of equity to a key executive is generally a positive signal, indicating management retention and alignment with shareholder interests, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of 46,659 Restricted Stock Units to the Chief Financial Officer indicates continued alignment of management's interests with shareholders.
• The vesting schedule encourages long-term retention of a key executive talent.

Risks

• The vesting of the Restricted Stock Units is subject to the employee's continued service with the company, meaning the shares could be forfeited if employment ceases before the vesting date.

Future Outlook

The grant of Restricted Stock Units with a future vesting date indicates an expectation of continued employment for the Chief Financial Officer and aligns his incentives with the company's long-term performance.

Industry Context

Insider equity grants, particularly Restricted Stock Units, are a common component of executive compensation packages across the biotechnology and pharmaceutical industries. They are designed to align executive interests with long-term shareholder value creation and promote executive retention.

Comparison to Industry Standards

• The grant of RSUs at a $0 price is standard practice for equity compensation in the biotechnology sector, similar to grants observed at companies like Gilead Sciences or Amgen for their executives.
• A one-year cliff vesting schedule for RSUs is a common, though sometimes shorter, vesting period compared to typical 3-4 year schedules seen in some tech or larger pharmaceutical companies, but it is not unusual for smaller biotech firms aiming for quicker retention incentives.
• The total beneficial ownership of 321,659 shares for a CFO in a company of DURECT's size is within typical ranges for executive equity holdings, reflecting a significant stake.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Financial Officer's long-term interests with shareholder value creation, as the value of the RSUs is tied to the company's stock performance.
• Employees: The RSU grant is part of executive compensation, which can set a precedent or reflect the company's overall approach to employee incentives, though this specific grant is for an executive.

Next Steps

• The 46,659 Restricted Stock Units are scheduled to vest on July 11, 2026, contingent on Timothy M. Papp's continued service with DURECT Corporation.

Key Dates

Keywords

DURECT Corporation, DRRX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Timothy M. Papp, Chief Financial Officer, Executive Compensation, Equity Grant